InVitro International Fundamental Company Report Including Financial, SWOT, Competitors and Industry Analysis

InVitro International Fundamental Company Report provides a complete overview of the company’s affairs. All available data is presented in a comprehensive and easily accessed format. The report includes financial and SWOT information, industry analysis, opinions, estimates, plus annual and quarterly forecasts made by stock market experts. The report also enables direct comparison to be made between InVitro International and its competitors. This provides our Clients with a clear understanding of InVitro International position in the Pharmaceuticals and Biotechnology Industry.

Scope

• The report contains the company’s profile and data about the owners, senior executives, locations, subsidiaries, markets, products, and company history.
• The SWOT-analysis provides information about the company’s strengths, weaknesses, opportunities, and possible threats against it.
• The report outlines the main financial ratios pertaining to profitability, margin analysis, asset turnover, credit ratios, and company’s long-term solvency.
• It also shows the company’s income statement and ratio trend-charts, with balance sheets and cash flows presented on an annual and quarterly basis.
• Company’s financial ratios are directly compared with those of its competitors through industry averages.
• The report provides relevant news, an analysis of PR-activity, and stock price movements.
• The latter are correlated with pertinent news and press releases, and annual and quarterly forecasts are given by a variety of experts and market research firms.

The benefits of buying the Report are as follows:

• Readers will gain an unrivalled in-depth knowledge about the company.
• The report will help the management of your business environment. This will be achieved through the report’s unique analysis of both the market and company’s competitors, and by providing detailed information about the internal and external factors that affect the relevant industry.
• Your company’s business and sales activities will be boosted by gaining an insight into your competitors’ businesses.
• The report will help you to find prospective partners and suppliers.
• The annual profitability data provided in the report will assist and strengthen your company’s decision-making processes.

About InVitro International

InVitro International (the Company or InVitro) was incorporated in California in 1985. The Company is engaged in the manufacture and sale of proprietary and preventive products and services directed to human and environmental safety. The Company distributes child safety and identification products and manufactures and markets proprietary in vitro assay kits and systems to detect, rank and predict the potential level of irritancy, toxicity or corrosivity of substances on human eye and/or skin tissue. Since late June 1996, the Company has marketed the Guardian DNA* child safety system through hospitals and other institutional markets.

In vitro tests sold by the Company principally include its IRRITECTION Assay System to evaluate potential for dermal and ocular irritation and CORROSITEX assays to determine Packing Group corrosivity level classifications within regulatory guidelines applicable to the transport and storage of chemicals, formulations and hazardous waste. These assays are principally used by manufacturers and others to verify product safety of consumer, household and industrial products, enable compliance with transportation and environmental regulations and assist in evaluation of workplace safety.

Products and Services

Guardian DNA Child Identification and Safety

The Company entered into a Distributorship Agreement on March 11, 1996 to market the Guardian-DNA identification system developed and supplied by Miragen Inc (Miragen), of Irvine, California.

Child Safety and Identification

The Guardian DNA product and service is a system that provides a reliable means of permitting the positive identification of a child at birth and for many years after the child's DNA sample was originally collected. Guardian DNA therefore addresses the requirements of parents who desire a means of positive long-term identification. Guardian DNA also provides educational tools for parents to protect their children in today's society.

Guardian DNA Sales and Marketing

The market targeted by the Company included institutions and professionals servicing pregnant women.

IRRITECTION Ocular and Dermal Assay System

InVitro originally introduced its EYTEX test kits in 1989 to assess ocular (eye) irritation and its SKINTEX test kits in 1990 to evaluate dermal (skin) irritation. The products were enhanced significantly and introduced to the market in July 1995 as the IRRITECTION Assay System.

The Company's IRRITECTION Assay System is a rapid, accurate, objective, reproducible and relatively inexpensive procedure for determining ocular and dermal irritancy potential. The Company produces various IRRITECTION test kits, which are directed to different applications and characteristics of products to be tested. Different tests are provided to clear, water-soluble products; insoluble, colored or opaque products; products with low surface tension; and alkaline products.

The IRRITECTION Assay System, as enhanced, is an application-driven irritation testing system. Designed to upgrade and enhance EYTEX and SKINTEX test kits, IRRITECTION assays are available in four basic variations, with a single unifying testing system directed to several specific markets. Targeted markets include industrial chemicals; industrial cleaners; petrochemicals; cosmetics; surfactants; and workplace health and safety, particularly for textile and dye manufacturing.

In addition to its assay test kits, InVitro offers a laboratory system, which includes an automated microplate reader and other supplies and components necessary for a customer to perform the IRRITECTION Assay System tests. The computer-driven microplate reader introduced in 1995 reduces total assay processing time and provides a user-friendly testing protocol. InVitro also sells a proprietary computer software program that is used in conjunction with the IRRITECTION Assay System for data analysis and quality control.

The Company currently offers IRRITECTION test kits for 16 different applications, each kit containing components to test from five to 10 samples.

CORROSITEX Packing Group Classification:

The Company introduced CORROSITEX during 1993 for Packing Group classification of corrosive chemicals, formulations and hazardous waste in response to United Nations guidelines and U.S. Department of Transportation (DOT) regulations originally implemented in October 1993.

CORROSITEX is a cost-effective, rapid in vitro alternative to measure the corrosivity level of chemicals, formulations and hazardous waste for Packing Group classification. The CORROSITEX system includes a modification of the Company's patented dermal biobarrier (membranes with materials that mimic human skin) and a chemical detection system in a chamber beneath the biobarrier. The test sample is applied to the dermal biobarrier.

The DOT exemption permits the use of CORROSITEX for testing a wide variety of chemicals and compounds, including organic and inorganic acids and acid derivatives, acyl halides, alkylamines and polyalklamines, organic and inorganic bases, chlorosilanes, and metal halides and oxyhalides.

Customized Technology Services

InVitro's Customized Technology Services (CTS) Division works directly with prospects and customers to develop application-specific product enhancements.

Governmental Agencies

InVitro actively works with a variety of U.S and foreign government departments and agencies, having responsibility for monitoring hazardous materials, to solicit their support in promoting the use of in vitro irritancy and corrosivity testing. In addition to the DOT, in the U.S. these include the Department of Defense, which provides directives for remediation of military installations, the Environmental Protection Agency (EPA) and the Food and Drug Administration (FDA).

Competition

Guardian DNA: The Company’s competitors of Biological identification companies include Child Trace International, Inc., Safe-T-Child, QuestGen and BirthMark.

Other In Vitro Technologies: The Company’s competitors include Clonetics Corporation of San Diego, MatTek Corporation of Ashland and Micro Devices Company of Menlo Park.

Contents

RESEARCH METHODOLOGY

DISCLAIMER

1. INVITRO INTERNATIONAL COMPANY PROFILE

1.1. Key facts
1.2. Financial Performance
1.3. Key Executives
1.4. Ownership and Major Holders
1.5. Company History

2. INVITRO INTERNATIONAL BUSINESS OVERVIEW

2.1. Business Description
2.2. Major Products and Services
2.3. Markets and Sales Activities
2.4. Locations, Subsidiaries, Operating Units

3. INVITRO INTERNATIONAL SWOT ANALYSIS

3.1. Overview
3.2. Strengths
3.3. Weaknesses
3.4. Opportunities
3.5. Threats

4. INVITRO INTERNATIONAL FINANCIAL ANALYSIS

4.1. Financial Statements
  4.1.1. Income Statement
  4.1.2. Balance Sheet
  4.1.3. Cash Flow
4.2. Financial Ratios
  4.2.1. Profitability
  4.2.2. Margin Analysis
  4.2.3. Asset Turnover
  4.2.4. Credit Ratios
  4.2.5. Long-Term Solvency
  4.2.6. Growth Over Prior Year
  4.2.7. Financial Ratios Charts
4.3. Stock Market Snapshot

5. INVITRO INTERNATIONAL COMPETITORS AND INDUSTRY ANALYSIS

5.1. InVitro International Direct Competitors
5.2. Comparison of InVitro International and Direct Competitors Financial Ratios
5.3. Comparison of InVitro International and Direct Competitors Stock Charts
5.4. InVitro International Industry Analysis
  5.4.1. Pharmaceuticals and Biotechnology Industry Snapshot
  5.4.2. InVitro International Industry Position Analysis

6. INVITRO INTERNATIONAL NEWS & EVENTS

6.1. News & PR Activity Analysis
6.2. IR Corporate News
6.3. Marketing News
6.4. Corporate Events

7. INVITRO INTERNATIONAL EXPERTS REVIEW

7.1. Experts Opinion
7.2. Experts Estimates

APPENDIX 1: RATIO DEFINITIONS

LIST OF TABLES

Table 1. InVitro International Key Facts
Table 2. InVitro International Profitability
Table 3. InVitro International Management Effectiveness
Table 4. InVitro International Income Statement Key Figures
Table 5. InVitro International Balance Sheet Key Figures
Table 6. InVitro International Cash Flow Statement Key Figures
Table 7. Financial Performance Abbreviation Guide
Table 8. InVitro International Key Executives
Table 9. InVitro International Key Executives Biographies *
Table 10. InVitro International Key Executives Compensations *
Table 11. InVitro International Key Executives Stock Options *
Table 12. InVitro International Major Shareholders
Table 13. InVitro International History
Table 14. InVitro International Products
Table 15. InVitro International Revenues by Product
Table 16. InVitro International Revenues by Region
Table 17. InVitro International Offices and Representations
Table 18. InVitro International SWOT Analysis
Table 19. InVitro International Income Statement 2008-2011 Including 4-years Trends
Table 20. InVitro International Income Statement Latest 4 Quarters Including Trends
Table 21. InVitro International Balance Sheet 2008-2011 Including Trends
Table 22. InVitro International Balance Sheet Latest 4 Quarters Including Trends
Table 23. InVitro International Cash Flow 2008-2011 Including Trends
Table 24. InVitro International Cash Flow Latest 4 Quarters Including Trends
Table 25. InVitro International Profitability Ratios
Table 26. InVitro International Margin Analysis Ratios
Table 27. InVitro International Asset Turnover Ratios
Table 28. InVitro International Credit Ratios
Table 29. InVitro International Long-Term Solvency Ratios
Table 30. InVitro International Financial Ratios Growth Over Prior Year
Table 31. InVitro International Capital Market Snapshot
Table 32. InVitro International Direct Competitors Key Facts
Table 33. InVitro International Direct Competitors Profitability Ratios
Table 34. InVitro International Direct Competitors Margin Analysis Ratios
Table 35. InVitro International Direct Competitors Asset Turnover Ratios
Table 36. InVitro International Direct Competitors Credit Ratios
Table 37. InVitro International Direct Competitors Long-Term Solvency Ratios
Table 38. Pharmaceuticals and Biotechnology Industry Statistics
Table 39. InVitro International Industry Position
Table 40. InVitro International vs. Industry Income Statement Analysis
Table 41. InVitro International vs. Industry Balance Sheet Analysis
Table 42. InVitro International vs. Industry Cash Flow Analysis
Table 43. InVitro International vs. Industry Ratios Comparison
Table 44. InVitro International Consensus Recommendations*
Table 45. InVitro International Analyst Recommendation Summary*
Table 46. InVitro International Price Target Summary*
Table 47. InVitro International Experts Recommendation Trends*
Table 48. InVitro International Revenue Estimates Analysis*
Table 49. InVitro International Earnings Estimates Analysis*
Table 50. InVitro International Historical Surprises*
Table 51. InVitro International Revenue Estimates Trend*
Table 52. InVitro International Earnings Estimates Trend*
Table 53. InVitro International Revenue Revisions*
Table 54. InVitro International Earnings Revisions*

LIST OF FIGURES

Figure 1. InVitro International Annual Revenues in Comparison with Cost of Goods Sold and Gross Profit
Figure 2. InVitro International Profit Margin Chart
Figure 3. InVitro International Operating Margin Chart
Figure 4. InVitro International Return on Equity (ROE) Chart
Figure 5. InVitro International Return on Assets (ROA) Chart
Figure 6. InVitro International Debt to Equity Chart
Figure 7. InVitro International Current Ratio Chart
Figure 8. InVitro International 1-year Stock Charts
Figure 9. InVitro International 5-year Stock Charts
Figure 10. InVitro International vs. Main Indexes 1-year Stock Chart
Figure 11. InVitro International vs. Direct Competitors 1-year Stock Charts
Figure 12. InVitro International Article Density Chart

* – Data availability depends on company’s security policy.
The complete financial data is available for public traded companies.

The above Company Fundamental Report is a half-ready report.
It means that we have all necessary data in our database to prepare the report but need 2-3 days to complete it. During this time we are also updating the report with respect to the current moment. So, you can get up-to-date version for the same price.